Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
- 17 March 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (7) , 3677-3693
Abstract
Many chemotherapeutics, such as paclitaxel, are administered intravenously as they suffer from poor oral bioavailability, partly because of efflux mechanism of P-glycoprotein in the intestinal epithelium. To date, no drug has been approved by the U.S. Food and Drug Administration (FDA) that selectively blocks this efflux pump. We sought to identify a compound that selectively inhibits P-glycoprotein in the gastrointestinal mucosa with poor oral bioavailability, thus eliminating the issues such as bone marrow toxicity associated with systemic inhibition of P-glycoprotein. Here, we describe the discovery of highly potent, selective, and poorly orally bioavailable P-glycoprotein inhibitor 14 (encequidar). Clinically, encequidar was found to be well tolerated and minimally absorbed; and importantly, it enabled the oral delivery of paclitaxel.Keywords
This publication has 71 references indexed in Scilit:
- Development and Evaluation of a Novel Microemulsion Formulation of Elacridar to Improve its BioavailabilityJournal of Pharmaceutical Sciences, 2013
- Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance ModulatorsThe AAPS Journal, 2009
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein researchFEBS Letters, 2005
- The Remarkable Transport Mechanism of P-Glycoprotein: A Multidrug TransporterJournal of Bioenergetics and Biomembranes, 2005
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Cremophor ELEuropean Journal of Cancer, 2001
- Induction and Inhibition of Intestinal P-glycoprotein and Effects on Etoposide AbsorptionDrug Metabolism and Pharmacokinetics, 1993